FindMyKOL
Clinical trialNCT05366829RecruitingPhase 2Interventional

Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma

NCT05366829 is a phase 2 interventional trial sponsored by Rutgers, The State University of New Jersey. As of 21 Nov 2026, it is recruiting participants. It studies Tislelizumab in Carcinoma, Hepatocellular and Liver Cell Carcinoma. The registry lists an enrollment of 35 participants at 2 sites in 1 country. The registry lists a start date of 25 Jul 2022 and a primary completion date of 1 Jun 2027. One of its registered investigators has a FindMyKOL profile.

SponsorRutgers, The State University of New JerseyEnrollment35Carcinoma, HepatocellularLiver Cell Carcinoma
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT05366829
FieldValue
Registry IDNCT05366829
StatusRecruiting
PhasePhase 2
Study typeInterventional trial
Lead sponsorRutgers, The State University of New Jersey
Enrollment35
Registered sites2
Countries1
ConditionsCarcinoma, Hepatocellular and Liver Cell Carcinoma
DrugsTislelizumab
Start25 Jul 2022
Primary completion1 Jun 2027
Study completion1 Jun 2027
Last update posted20 Jan 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The investigators hypothesize that the addition of Tislelizumab after definitive local therapy for locally advanced inoperable Hepatocellular carcinoma (HCC) will synergize with local therapy as well as treat micro metastatic disease and improve one year progression-free survival rates for participants and optimize local control.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

New Jersey, United States1 site, 1 recruiting
  • Rutgers Cancer Institute of New Jersey

    New Brunswick

    Recruiting
New York, United States1 site, 1 recruiting
  • Montefiore Medical Center

    The Bronx

    Recruiting

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew York: 1 site, 1 recruitingNY1MassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew Jersey: 1 site, 1 recruitingNJ1ConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT05366829

Each answer restates registry values shown on this page.

What is NCT05366829?

NCT05366829 is a phase 2 interventional trial sponsored by Rutgers, The State University of New Jersey. It studies Tislelizumab in Carcinoma, Hepatocellular and Liver Cell Carcinoma.

Is NCT05366829 recruiting?

As of 21 Nov 2026, it is recruiting participants. 2 of its 2 sites list their own status as recruiting.

Who leads NCT05366829?

The registry names Salma Jabbour, MD (principal investigator, Rutgers Cancer Institute of New Jersey) as the overall official.

Where does NCT05366829 run?

The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT05366829 study?

The registered drug and biological interventions are Tislelizumab.

When is NCT05366829 expected to complete?

The registry lists a primary completion date of 1 Jun 2027 and a study completion date of 1 Jun 2027. The sponsor last updated the record on 20 Jan 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.